MX2020010444A - Complejos de péptidos bicíclicos en heterotándem. - Google Patents
Complejos de péptidos bicíclicos en heterotándem.Info
- Publication number
- MX2020010444A MX2020010444A MX2020010444A MX2020010444A MX2020010444A MX 2020010444 A MX2020010444 A MX 2020010444A MX 2020010444 A MX2020010444 A MX 2020010444A MX 2020010444 A MX2020010444 A MX 2020010444A MX 2020010444 A MX2020010444 A MX 2020010444A
- Authority
- MX
- Mexico
- Prior art keywords
- peptide complexes
- bicyclic peptide
- heterotandem bicyclic
- heterotandem
- binds
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 5
- 125000002619 bicyclic group Chemical group 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 239000003446 ligand Substances 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 abstract 1
- 210000002865 immune cell Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/50—Cyclic peptides containing at least one abnormal peptide link
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
- C07K17/02—Peptides being immobilised on, or in, an organic carrier
- C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1805492.4A GB201805492D0 (en) | 2018-04-04 | 2018-04-04 | Heterotandem Bicyclic peptide complexes |
| GBGB1820981.7A GB201820981D0 (en) | 2018-12-21 | 2018-12-21 | Heterotandem bicyclic peptide complexes |
| PCT/GB2019/050951 WO2019193328A1 (en) | 2018-04-04 | 2019-04-02 | Heterotandem bicyclic peptide complexes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020010444A true MX2020010444A (es) | 2021-01-08 |
Family
ID=66175434
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020010444A MX2020010444A (es) | 2018-04-04 | 2019-04-02 | Complejos de péptidos bicíclicos en heterotándem. |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11453703B2 (enExample) |
| EP (1) | EP3774851A1 (enExample) |
| JP (2) | JP7551500B2 (enExample) |
| KR (1) | KR20200139236A (enExample) |
| CN (1) | CN112236442A (enExample) |
| AU (2) | AU2019247795B2 (enExample) |
| BR (1) | BR112020020349A2 (enExample) |
| CA (1) | CA3095582A1 (enExample) |
| IL (1) | IL277717A (enExample) |
| MX (1) | MX2020010444A (enExample) |
| SG (1) | SG11202009773VA (enExample) |
| WO (1) | WO2019193328A1 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2708459C2 (ru) | 2014-10-29 | 2019-12-09 | БайсиклРД Лимитед | Бициклические пептидные лиганды, специфичные для мт1-ммр |
| GB201607827D0 (en) | 2016-05-04 | 2016-06-15 | Bicycle Therapeutics Ltd | Bicyclic peptide-toxin conjugates specific for MT1-MMP |
| CN110603261A (zh) | 2016-12-23 | 2019-12-20 | 拜斯科阿迪有限公司 | 具有新型键结构的肽衍生物 |
| US10899798B2 (en) | 2017-06-26 | 2021-01-26 | Bicyclerd Limited | Bicyclic peptide ligands with detectable moieties and uses thereof |
| JP7670481B2 (ja) | 2017-08-04 | 2025-04-30 | バイスクルテクス・リミテッド | Ｃｄ１３７に対して特異的な二環式ペプチドリガンド |
| GB201721265D0 (en) | 2017-12-19 | 2018-01-31 | Bicyclerd Ltd | Bicyclic peptide ligands specific for EphA2 |
| TWI825046B (zh) | 2017-12-19 | 2023-12-11 | 英商拜西可泰克斯有限公司 | Epha2特用之雙環胜肽配位基 |
| JP2021514953A (ja) | 2018-02-23 | 2021-06-17 | バイスクルテクス・リミテッド | 多量体二環式ペプチドリガンド |
| SG11202009773VA (en) * | 2018-04-04 | 2020-10-29 | Bicycletx Ltd | Heterotandem bicyclic peptide complexes |
| US11180531B2 (en) | 2018-06-22 | 2021-11-23 | Bicycletx Limited | Bicyclic peptide ligands specific for Nectin-4 |
| GB201810316D0 (en) | 2018-06-22 | 2018-08-08 | Bicyclerd Ltd | Peptide ligands for binding to EphA2 |
| GB201820325D0 (en) | 2018-12-13 | 2019-01-30 | Bicyclerd Ltd | Bicyclic peptide ligands specific for psma |
| GB201820288D0 (en) | 2018-12-13 | 2019-01-30 | Bicycle Tx Ltd | Bicycle peptide ligaands specific for MT1-MMP |
| GB201820295D0 (en) | 2018-12-13 | 2019-01-30 | Bicyclerd Ltd | Bicyclic peptide ligands specific for MT1-MMP |
| EP3897849A1 (en) * | 2018-12-21 | 2021-10-27 | BicycleTx Limited | Bicyclic peptide ligands specific for pd-l1 |
| EP3897850A1 (en) * | 2018-12-21 | 2021-10-27 | Bicyclerd Limited | Bicyclic peptide ligands specific for pd-l1 |
| CA3137095A1 (en) | 2019-05-09 | 2020-11-12 | Bicycletx Limited | Bicyclic peptide ligands specific for ox40 |
| TWI860386B (zh) | 2019-07-30 | 2024-11-01 | 英商拜西可泰克斯有限公司 | 異質雙環肽複合物 |
| WO2021028686A1 (en) * | 2019-08-13 | 2021-02-18 | Bicycletx Limited | Modified multimeric bicyclic peptide ligands |
| EP4464721B1 (en) | 2019-10-03 | 2025-06-11 | BicycleTX Limited | Heterotandem bicyclic peptide complexes |
| GB201914872D0 (en) * | 2019-10-15 | 2019-11-27 | Bicycletx Ltd | Bicyclic peptide ligand drug conjugates |
| KR20230074721A (ko) | 2020-08-17 | 2023-05-31 | 바이사이클티엑스 리미티드 | Nectin-4에 특이적인 이환 콘쥬게이트 및 이의 용도 |
| GB202016331D0 (en) * | 2020-10-15 | 2020-12-02 | Bicyclerd Ltd | Bicyclic peptide ligand drug conjugates |
| WO2022148975A1 (en) * | 2021-01-08 | 2022-07-14 | Bicycletx Limited | Heterotandem bicyclic peptide complexes |
| US20250186539A2 (en) * | 2021-01-11 | 2025-06-12 | Bicycletx Limited | Methods for treating cancer |
| WO2022253051A1 (zh) * | 2021-06-01 | 2022-12-08 | 南京明德新药研发有限公司 | 多肽偶联药物及其应用 |
| US20250121076A1 (en) * | 2021-08-17 | 2025-04-17 | Medshine Discovery Inc. | Polypeptide drug conjugate having novel structure and application thereof |
| TWI803993B (zh) * | 2021-09-28 | 2023-06-01 | 廖嘉鴻 | 環胜肽自組裝3d微粒裝置及其製造方法 |
| MX2024003876A (es) * | 2021-09-29 | 2024-04-19 | Conjustar Zhuhai Biologics Co Ltd | Conjugado farmaco-polipeptido triciclico y sus aplicaciones. |
| CN115819618B (zh) * | 2022-09-16 | 2023-10-27 | 哈尔滨工业大学 | 一种光激活的纳抗偶联物二聚化诱导剂pancid及其应用 |
| WO2025248261A1 (en) | 2024-05-31 | 2025-12-04 | Bicycletx Limited | Method for identifying patients |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1452868A2 (en) | 2003-02-27 | 2004-09-01 | Pepscan Systems B.V. | Method for selecting a candidate drug compound |
| US7288638B2 (en) | 2003-10-10 | 2007-10-30 | Bristol-Myers Squibb Company | Fully human antibodies against human 4-1BB |
| EP1844337B1 (en) | 2005-01-24 | 2013-07-03 | Pepscan Systems B.V. | Binding compounds, immunogenic compounds and peptidomimetics |
| DK2257624T5 (da) | 2008-02-05 | 2012-09-10 | Medical Res Council | Fremgangsmåder og sammensætninger |
| GB0913775D0 (en) * | 2009-08-06 | 2009-09-16 | Medical Res Council | Multispecific peptides |
| CA2777242A1 (en) * | 2009-10-14 | 2011-04-21 | Merrimack Pharmaceuticals, Inc. | Bispecific binding agents targeting igf-1r and erbb3 signalling and uses thereof |
| JP2013518807A (ja) * | 2010-02-04 | 2013-05-23 | メディカル リサーチ カウンシル | 多重特異性ペプチド |
| CN103906865B (zh) * | 2011-10-07 | 2017-12-08 | 拜斯科医疗有限公司 | 结构化多肽特异性的调控 |
| US20140274759A1 (en) | 2013-03-15 | 2014-09-18 | Bicycle Therapeutics Limited | Modification of polypeptides |
| US20170165334A1 (en) * | 2015-12-11 | 2017-06-15 | Tianxin Wang | Methods to Treat Diseases with Protein, Peptide, Antigen Modification and Hemopurification |
| RU2708459C2 (ru) * | 2014-10-29 | 2019-12-09 | БайсиклРД Лимитед | Бициклические пептидные лиганды, специфичные для мт1-ммр |
| MA45328A (fr) * | 2016-04-01 | 2019-02-06 | Avidity Biosciences Llc | Compositions acide nucléique-polypeptide et utilisations de celles-ci |
| WO2017182672A1 (en) | 2016-04-22 | 2017-10-26 | Alligator Bioscience Ab | Novel bispecific polypeptides against cd137 |
| JP7670481B2 (ja) | 2017-08-04 | 2025-04-30 | バイスクルテクス・リミテッド | Ｃｄ１３７に対して特異的な二環式ペプチドリガンド |
| GB201721265D0 (en) | 2017-12-19 | 2018-01-31 | Bicyclerd Ltd | Bicyclic peptide ligands specific for EphA2 |
| TWI825046B (zh) | 2017-12-19 | 2023-12-11 | 英商拜西可泰克斯有限公司 | Epha2特用之雙環胜肽配位基 |
| JP2021514953A (ja) | 2018-02-23 | 2021-06-17 | バイスクルテクス・リミテッド | 多量体二環式ペプチドリガンド |
| SG11202009773VA (en) * | 2018-04-04 | 2020-10-29 | Bicycletx Ltd | Heterotandem bicyclic peptide complexes |
| US11180531B2 (en) * | 2018-06-22 | 2021-11-23 | Bicycletx Limited | Bicyclic peptide ligands specific for Nectin-4 |
| GB201810316D0 (en) | 2018-06-22 | 2018-08-08 | Bicyclerd Ltd | Peptide ligands for binding to EphA2 |
| EP3946462A1 (en) | 2019-04-02 | 2022-02-09 | BicycleTX Limited | Bicycle toxin conjugates and uses thereof |
| TWI860386B (zh) | 2019-07-30 | 2024-11-01 | 英商拜西可泰克斯有限公司 | 異質雙環肽複合物 |
| EP4464721B1 (en) | 2019-10-03 | 2025-06-11 | BicycleTX Limited | Heterotandem bicyclic peptide complexes |
| US20230025916A1 (en) | 2019-11-27 | 2023-01-26 | Bicycle TX Limited | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR EphA2 AND USES THEREOF |
-
2019
- 2019-04-02 SG SG11202009773VA patent/SG11202009773VA/en unknown
- 2019-04-02 AU AU2019247795A patent/AU2019247795B2/en active Active
- 2019-04-02 KR KR1020207031802A patent/KR20200139236A/ko not_active Ceased
- 2019-04-02 BR BR112020020349-1A patent/BR112020020349A2/pt unknown
- 2019-04-02 JP JP2020554265A patent/JP7551500B2/ja active Active
- 2019-04-02 EP EP19717554.0A patent/EP3774851A1/en active Pending
- 2019-04-02 US US16/372,692 patent/US11453703B2/en active Active
- 2019-04-02 WO PCT/GB2019/050951 patent/WO2019193328A1/en not_active Ceased
- 2019-04-02 CN CN201980037963.XA patent/CN112236442A/zh active Pending
- 2019-04-02 CA CA3095582A patent/CA3095582A1/en active Pending
- 2019-04-02 MX MX2020010444A patent/MX2020010444A/es unknown
-
2020
- 2020-10-01 IL IL277717A patent/IL277717A/en unknown
-
2022
- 2022-05-12 US US17/663,169 patent/US20230008076A1/en active Pending
-
2024
- 2024-02-05 JP JP2024015762A patent/JP2024062998A/ja active Pending
- 2024-07-25 AU AU2024205105A patent/AU2024205105A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2021520378A (ja) | 2021-08-19 |
| JP2024062998A (ja) | 2024-05-10 |
| US20210299210A2 (en) | 2021-09-30 |
| JP7551500B2 (ja) | 2024-09-17 |
| SG11202009773VA (en) | 2020-10-29 |
| US11453703B2 (en) | 2022-09-27 |
| EP3774851A1 (en) | 2021-02-17 |
| CN112236442A (zh) | 2021-01-15 |
| US20190307836A1 (en) | 2019-10-10 |
| KR20200139236A (ko) | 2020-12-11 |
| WO2019193328A1 (en) | 2019-10-10 |
| AU2024205105A1 (en) | 2024-10-10 |
| BR112020020349A2 (pt) | 2021-01-05 |
| AU2019247795B2 (en) | 2024-08-15 |
| IL277717A (en) | 2020-11-30 |
| US20230008076A1 (en) | 2023-01-12 |
| CA3095582A1 (en) | 2019-10-10 |
| AU2019247795A1 (en) | 2020-11-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020010444A (es) | Complejos de péptidos bicíclicos en heterotándem. | |
| EP4592309A3 (en) | Heterotandem bicyclic peptide complexes | |
| MX2022001290A (es) | Complejos de peptido biciclico en heterotandem. | |
| MX2023008168A (es) | Complejos peptidicos biciclicos heterotandem. | |
| PH12019502875A1 (en) | Antibody molecules to cd73 and uses thereof | |
| ZA201708265B (en) | Tigit-binding agents and uses thereof | |
| NZ753515A (en) | Methods for treatment of cancer comprising tigit-binding agents | |
| WO2019232244A3 (en) | Antibody molecules to cd73 and uses thereof | |
| PH12019500270A1 (en) | Combination therapy for cancer | |
| MX2022011818A (es) | Metodos y composiciones para el direccionamiento de canceres de celulas t. | |
| PH12017500190B1 (en) | An anti-ctla4 monoclonal antibody or antigen binding fragment thereof, a pharmaceutical composition and use | |
| PH12016501411B1 (en) | Bifunctional cytotoxic agents | |
| PH12021551425A1 (en) | Bifunctional anti-pd-1/sirpa molecule | |
| PH12019550233A1 (en) | A novel anti-c-met antibody and use thereof | |
| MX2018005830A (es) | Composiciones y metodos para tratar enfermedades autoinmunes y canceres. | |
| EA201992318A1 (ru) | Композиции и способы для диагностики и лечения рака предстательной железы с использованием молекулы, связывающей прогастрин | |
| PH12020551556A1 (en) | Drug conjugates of cmet monoclonal binding agents, and uses thereof | |
| WO2019168897A3 (en) | Methods for treating cancer using combinations of anti-btnl2 and immune checkpoint blockade agents | |
| EP4541423A3 (en) | Dosing regimen of avelumab for the treatment of cancer | |
| EA202092388A1 (ru) | Гетеротандемные бициклические пептидные комплексы | |
| MX2024004429A (es) | Regimenes de dosificacion del anticuerpo anti-ctla-4. | |
| MX2019013019A (es) | USO DE 3,16-DIACETADO DE 26-AZIDO-22-OXOCOLEST-5-3ß, 16ß-DIILO COMO AGENTE ANTICANCERIGENO. | |
| AR119512A1 (es) | Complejo de péptidos bicíclicos hetero-tándem | |
| EA201792249A1 (ru) | Комбинированная терапия злокачественной опухоли |